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Aggregating sequences that occur in many proteins
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Aggregation is a sequence-speciﬁc process, nucleated by short aggregation-prone regions
(APRs) that can be exploited to induce aggregation of proteins containing the same APR.
Here, we ﬁnd that most APRs are unique within a proteome, but that a small minority of APRs
occur in many proteins. When aggregation is nucleated in bacteria by such frequently
occurring APRs, it leads to massive and lethal inclusion body formation containing a large
number of proteins. Buildup of bacterial resistance against these peptides is slow. In addition,
the approach is effective against drug-resistant clinical isolates of Escherichia coli and Aci-
netobacter baumannii, reducing bacterial load in a murine bladder infection model. Our results
indicate that redundant APRs are weak points of bacterial protein homeostasis and that
targeting these may be an attractive antibacterial strategy.
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Loss of protein homeostasis
1 is a constant threat for any living
cell due to the highly crowded intracellular environment that
brings into close proximity a large variety of polypeptides
that need to undergo error-prone folding reactions in order to
attain their native conformation2. To control this threat, cells
have evolved a complex network of molecular chaperones, pro-
teases, and other specialized molecules3. In spite of these cellular-
response mechanisms, human protein-folding pathologies have
made it clear that under persistent exposure to aggregating pro-
teins, for example, as a result of mutation, protein homeostasis
can eventually break down, which ultimately results in cell death4.
On the other hand, protein aggregation turns out to be a highly
ordered and speciﬁc process: aggregation is more efﬁcient
between similar than between unrelated polypeptides5–7. At a
mechanistic level, protein aggregation is mediated by short
(between 5 and 15 residues) aggregation-prone sequence seg-
ments (called APRs), which on average occur at least once every
100 amino acids in the primary polypeptide sequence8. These
APRs are generally sequence segments constituting the hydro-
phobic core of globular proteins or protein–protein interaction
interfaces9. While forming the most stable part of the native
proteins, in unfolded proteins, APRs can also self-assemble with
identical APRs from another protein to form β-structured
aggregates10. The risk of aggregation is thus the highest during
translation before the protein attains its native conformation11.
As the sequence of most APRs is unique within a given pro-
teome7, aggregation will generally be restricted to identical pro-
teins. However, a minority of APRs (or close homologs thereof)
are found in several and sometimes many different proteins7.
Given the sequence speciﬁcity of aggregation, this suggests that
these proteins could coaggregate via such a common APR. The
redundancy of these APRs therefore also suggests that they might
constitute particularly vulnerable proteomic segments, and that
under conditions of stress, these might act as hot spots for the
initiation of proteostatic collapse.
In order to test this concept, here, we screen 125 aggregating
sequences that have a high degree of redundancy in the Escher-
ichia coli proteome. In this manner, one peptide containing this
APR could potentially affect the folding of many proteins con-
taining highly similar APRs. Using this strategy, we identify
several peptides that efﬁciently induce bactericidal protein
aggregation and inclusion body (IB) formation in E. coli. This
process is bactericidal to E. coli as well as Acinetobacter bau-
mannii, including clinical strains that are resistant to current
antibiotics. Analyzing these peptides in E. coli in more detail
using several molecular and proteomic approaches, we ﬁnd that
these peptides induce widespread aggregation of bacterial pro-
teins, resulting in bactericidal aggregation cascades involving
hundreds of proteins. Moreover, the peptides effectively reduce
bacterial load in a murine bladder E. coli infection model, sug-
gesting that redundant APRs in bacterial proteomes can be tar-
geted for therapeutic purposes.
Results
Redundant aggregating sequences are rare. We used the sta-
tistical thermodynamics algorithm TANGO to analyze the
aggregation propensity and APR redundancy of the E. coli strain
O157:H7 proteome. This yielded 3,535 APR sequences of at least
six amino acids in length with a TANGO score of at least 20%.
Given the length limitation of roughly 20 amino acids in solid-
phase peptide synthesis with regard to yield and purity, our
peptide design imposes a maximum length on the APRs that can
be accommodated (APRs will be incorporated in a tandem repeat
design peptide comprising twice the APR ﬂanked by three gate-
keeper arginine residues and linked by a single proline; see
below), forcing us to restrict our experimental analysis to the
1,542 APRs with a length of seven amino acids. To analyze the
redundancy of these sequences, we calculated for each of these
APRs the number of times their sequence occurred in other
proteins in the E. coli proteome, considering zero, one, or two
amino acid mutations (Fig. 1a). This shows that for more than
80% of the seven-residue APRs, their exact sequence is unique in
the E. coli proteome, while virtually no heptameric APR is found
in more than ﬁve different proteins (Fig. 1a, red line). This
observation might be related to the previous ﬁnding that selective
pressure shapes sequence divergence in repeat-domain proteins
such as titin in order to avoid interdomain aggregation12.
Allowing one mutation in the APR (85% APR sequence identity),
we found that the number of unique APRs drops to 20% (Fig. 1a,
blue line), but there is almost no heptameric APR sequence that
possesses more than 10 APR homologs with a single-point
mutation in other E. coli proteins. This suggests that while one
mutation is in many instances probably sufﬁcient to avoid
coaggregation (especially hydrophobic to charged-residue muta-
tions), several single-point mutations will still allow for coag-
gregation (especially conservative hydrophobic mutations), which
is conﬁrmed by previous observations6,13. Finally, allowing for
two mutations (70% APR sequence identity), we found that most
APRs have more than 10 homologous APRs (Fig. 1a, green line);
this suggests that at 70% sequence divergence (i.e., two mis-
matches in a heptameric sequence), coaggregation may be a rare
occurrence, although it should still not be excluded. Indeed,
Fig. 1a (green line) also suggests that high redundancy of two
mismatch mutations (above 30) is still to be avoided. Very similar
distributions of the number of homologous or identical APRs
could also be observed in other bacterial proteomes, including
Klebsiella pneumoniae, Pseudomonas aeruginosa, and A. bau-
mannii (Supplementary Fig. 1), suggesting that this is a universal
feature of bacterial proteomes.
To experimentally investigate the impact of APR redundancy
on the proteostatic robustness of the E. coli proteome, we ranked
APRs at the extreme of the redundancy distribution in Fig. 1a,
showing up to 10 matches with one mismatch mutation and up to
100 matches with two mutations, and selected the ﬁrst 75 most
frequently occurring sequences from this list (Supplementary
Table 1). The extreme values of these APRs are apparent from
Fig. 1b, showing an enrichment of tail values of the E. coli APR
redundancy distribution displayed in Fig. 1a. Counting all
amino acid substitutions as equal in terms of their likely
β-interaction with the bait sequence is only a very rough
approximation, but one that needs to be made since reliably
separating amino acid substitutions that are conducive of
β-interaction from those that are not is beyond the scope of
current prediction algorithms.
Redundant APRs cause bacterial cell death. In order to generate
efﬁcient aggregation seeds, here, we employed a tandem
repeat design previously validated14,15, in which the redundant
APR is incorporated as a tandem repeat separated by a linker
constituted by a single proline. In order to increase the colloidal
stability of these aggregating peptides, the APRs are ﬂanked by
aggregation gatekeepers, a class of residues that was previously
shown to reduce aggregation kinetics8,16,17. Since positively
charged residues have also been shown to help bacterial uptake18,
we selected arginine to obtain the following peptide layout:
R-APR-RR (Fig. 1c). To further modulate the kinetics of aggre-
gation of these peptides, we also added two variants of each of the
ﬁrst 25 peptides in the list by randomly mutating one residue in
the ﬁrst APR repeat to arginine (Supplementary Table 1). These
100 peptides were generated using solid-phase synthesis at 200-
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nmol scale and dissolved in dimethyl sulfoxide (DMSO) to a
theoretical stock concentration of 2 mM (by assuming 100%
synthesis efﬁciency).
As we were looking for peptides capable of inducing a lethal
proteostatic collapse, our primary screen consisted of measuring
the effect of our peptides on the growth of E. coli O157:H7 at
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Fig. 1 Proteome analysis, design, and screening of redundant APRs. a Distribution of the redundancy of APR sequences of length seven in the E. coli
proteome: percentage of identical sequences (red), one mismatch (blue), and two mismatches (green). b Same distribution as in a for the 75 most
redundant APRs in E. coli. c Design pattern for aggregating peptide screen. Tandem APRs are linked by a linker (a single proline residue) and embedded
between gatekeeper residues (GK; arginine residues). d, e APR redundancy for toxic versus nontoxic peptides considering one (d) or two (e) mismatches.
The bottom and top of the boxes are the ﬁrst and third quartiles, and the band inside the box represents the median. The whiskers encompass the
minimum and maximum of the data. Signiﬁcant differences were computed using Welch’s t test. f Time-killing curve of selected peptides (P14, P2, and
P5R) and ampicillin (Amp) against E. coli strain O157:H7 treated at MIC concentration (average and SD of three replicates). g–i Transmission electron
microcopy (TEM) of cross-sections of resin-embedded E. coli O157:H7, treated for 2 h with buffer (g), P2 peptide (h), and P105 peptide (i) at MIC
concentration. j Wide-ﬁeld structured illumination microscopy (SIM) image of E. coli O157:H7 treated with P2 and stained with the amyloid-speciﬁc dye
pFTAA (0.5 µM). k Monitoring of spontaneous buildup of resistance by monitoring the MIC value of E. coli O157: H7 cultures that are maintained on
sublethal doses (50% of MIC) of selected peptides (P14, P2, and P105) or ampicillin (Amp) for 36 days
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dilutions of the peptide corresponding to concentrations of 1, 6,
12, and 25 μg/mL. Although no peptide inhibited bacterial growth
at the highest dilution, 43 of them inhibited bacterial growth of
E. coli O157 at 25 μg/mL, of which 11 were still active at 12 μg/mL
and six had an apparent minimum inhibitory concentration
(MIC) value of 6 μg/mL (Supplementary Table 2). We separated
the original 75 APRs into two groups based on their inhibitor
activity: the hits listed in Supplementary Table 2 and the inactive
peptides. We then compared the sequence redundancy in the
E. coli proteome of the APRs in both groups and found that the
number of sequence matches found at both one and two
mutations distance were signiﬁcantly higher in the active group
than in the inactive group (Fig. 1d, e). This shows that a high APR
redundancy is associated to bacterial cell death, suggesting that
these sequences could indeed represent proteomic weak spots of
susceptibility for proteostatic collapse.
Bactericidal activity is associated to IB formation. In order to
investigate whether APR redundancy does result in proteostatic
collapse, we selected resynthesized and high-performance liquid
chromatography (HPLC)-puriﬁed four positive peptides from the
screen, P2, P5, P14, and P105, as well as three negative peptides,
P3, P4, and P11, and conﬁrmed their MIC and minimum bac-
tericidal concentration (MBC) values (Table 1). Analysis of the
rate of peptide bactericidal activity against E. coli O157:H7 (at
MIC concentration) showed that the peptides exerted full bac-
tericidal effect within 30 min to 2 h (Fig. 1f). Biophysical analysis
of the P2 peptide in vitro, using mass spectrometry (MS),
dynamic light scattering (DLS), Fourier transform infrared
spectroscopy, transmission electron microscopy (TEM), and
tinctorial assays conﬁrmed the intrinsic aggregation propensity of
the P2 peptide (Supplementary Note 1 and Supplementary Fig. 2).
Cross-section TEM of peptide-treated bacteria revealed the
widespread presence of large IBs, a hallmark of protein aggre-
gation in E. coli, suggesting that the peptides act by interfering
with bacterial proteostasis (Fig. 1g–i). These IBs, which are also
called large polar aggregates19, could be stained with pentameric
formyl thiophene acetic acid (pFTAA, Fig. 1j and supplementary
Fig. 3), an extensively characterized amyloid-speciﬁc dye20–22,
which speciﬁcally binds to amyloid-like aggregates as well as
disease-associated protein IBs22. This IB-staining pattern could be
observed for all bactericidal peptides, but not for any of the other
peptides, although some other pFTAA-positive structures could
be discerned (Supplementary Fig. 3). We conﬁrmed the cross-β-
structure content of IB using thioﬂavin-T staining and correlative
atomic force microscopy nanoimaging and Fourier transform
infrared spectroscopy (Supplementary Note 2 and Supplementary
Fig. 4). These data show that aggregation, resulting in cross-β-
structure-enriched IBs, is a crucial property of the bactericidal
peptide treatment.
When bacteria were repeatedly passaged on sublethal con-
centrations (50% of MIC) of the active peptides for a period of
36 days, no development of resistance was observed, whereas this
was the case for the control antibiotic ampicillin (Fig. 1k). These
data are supportive of a mode of action involving many targets
throughout the E. coli proteome. To investigate this in more
detail, peptide P2 was selected for further analysis. As a control,
we generated a variant of P2, called P2Pro, in which we
introduced proline substitutions at two positions in the APRs
(Table 1), which conserve the hydrophobicity but disrupt the
β-sheet propensity and hence reduce the aggregation propensity
of the peptides23. When we treated bacteria with the control
peptides, we obtained MIC values of more than 200 μg/mL,
indicating again that β-aggregation is key for the bactericidal
effect of P2.
We derivatized P2 with ﬂuorescein isothiocyanate (FITC) and
established that the conjugate retained its antibacterial activity
(MIC= 3 μg/mL against E. coli O157:H7) and quantiﬁed P2
uptake over time by ﬂow cytometry (Fig. 2a–f). Analysis of P2
uptake by E. coli O157:H7 showed that after 15 min, 97.7 ± 2.9%
(N= 4, mean and s.d.) of the cells are positive for FITC (Fig. 2b,
f), increasing to nearly 100% after 1 h and beyond (Fig. 2c–f). In
parallel, ﬂuorescence microscopy of treated E. coli O157:H7 at
MIC concentration conﬁrmed no enrichment at the cell
membrane of FITC-P2, but rather showed a clear accumulation
of ﬂuorescence in intracellular polar IBs from 15min onward
(Fig. 2g) that persisted at later time points (Fig. 2h) and thus
conﬁrmed the cross-section TEM images (Fig. 1g–i). Kinetics of
bacterial cell death as measured by colony-forming unit (CFU)
determination after P2 treatment (Fig. 2i) closely follow peptide
internalization and coincide with the appearance of IBs after
15 min of treatment (50% after 15 min). On the other hand,
bacterial cell death as monitored by propidium iodide (PI) uptake
as a result of membrane permeabilization increased more slowly
(2.1 ± 1.3% after 15 min to 85 ± 13.2% after 3 h, Fig. 2a–e,
summarized in Fig. 2j, N= 4). This was conﬁrmed by
morphological analysis using scanning electron microscopy
(SEM) (Supplementary Note 3 and Supplementary Fig. 5).
Together, these data demonstrate that P2 uptake and IB
formation occur in close succession, and this is followed by cell
death. Cell death precedes membrane disruption as signiﬁcant
growth inhibition is established coincidentally with IB formation
but before membrane permeability or deformation can be
observed. Importantly, all PI-positive cells stain positive for
aggregation by pFTAA (Fig. 2k) and when bacteria were treated
with FITC-P2Pro, which showed comparable uptake to P2
(Fig. 2f), no protein aggregation ensued (Fig. 2l) and hence no
cell death could be detected (Fig. 2l). This again shows that
aggregation of the peptide is essential to mediate its bactericidal
effect.
Protein aggregation is required for cell death. Bacterial IB
formation is a common event associated with cellular stress
including exposure to heat and, perhaps most famously, recom-
binant protein (over)expression24. This process, however, is often
transient and reversible and does not necessarily lead to bacterial
cell death. In fact, recombinant protein production in bacteria
relies to a large extent on the ability of bacteria to cope with IBs.
As an example, we measured the consequences of overexpressing
the highly aggregation-prone core domain of the human p53
protein (p53CD) on growth (Fig. 3a) and colony formation
(Fig. 3b) of E. coli BL21 cells, which are routinely used for
recombinant protein production. Although p53CD expression
resulted in a delay of the exponential growth phase, consistent
with cellular stress resulting from overexpression, there was no
Table 1 MIC and MBC values of selected peptides puriﬁed by
HPLC grade on E. coli O157
Puriﬁed
peptide
Sequences MIC
(μg/
mL)
MBC
(μg/mL)
P2 RGLGLALVRRPRGLGLALVRR 6 6
P2Pro RGLGPALPRRPRGLGPALPRR >100 >100
P5 RALLTTLLRRPRALLTTLLRR 6 6
P5R RRALLTTLLRRPRALLTTLLRR 12 12
P105 RALLRTLLRRPRALLTTLLRR 12 12
P14 RGLLALLARRPRGLLALLARR 6 6
MIC minimum inhibitory concentration, MBC minimum bactericidal concentration, HPLC high-
performance liquid chromatography
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effect on colony formation, showing that the stress in this con-
dition is not lethal. In order to understand why P2-induced IB
formation is irreversibly toxic, we compared the composition of
IBs puriﬁed from E. coli O157:H7 cells treated with P2 at MIC
concentration for 1 h with IBs puriﬁed from E. coli strain BL21
overnight overexpressing p53CD. Inspection of the resulting
samples by TEM conﬁrmed the successful puriﬁcation of these
IBs (Fig. 3c). The composition of IBs was subsequently analyzed
by Coomassie-stained sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) (Fig. 3d). The overall pattern of
Coomassie staining revealed that a large number of similar bac-
terial proteins are trapped in the IBs of both P2-treated E. coli
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Fig. 2 Uptake and inclusion body formation. a–e Fluorescence-activated cell sorting (FACS) analysis of 40,000 E. coli O157: H7 cells, measuring FITC
ﬂuorescence (x-axis) and propidium iodide (PI) ﬂuorescence (y-axis) of a untreated and heat-inactivated bacteria mixed at a ratio of 1:1 and b–e bacteria
treated for 15 min (b), 1 h (c), 3 h (d), and 6 h (e) with FITC-labeled P2 at MIC concentration. f Average population sizes of FITC-positive cells treated with
FITC-P2 or FITC-P2Pro from four independent experiments such as those shown in b–e. g Wide-ﬁeld structured illumination microscopy (SIM) image of E.
coli treated with FITC-P2 for 15 min and h for 1 h at MIC concentration. i Time-dependent cell death following P2 treatment (1 xMIC) as % CFU/mL, in E.
coli O157:H7. j Average population sizes of PI-positive cells (propidium iodide) from four independent FACS experiments such as those shown in a–e. k
FACS analysis of 40,000 E. coli O157:H7 cells, measuring pFTAA ﬂuorescence (x-axis) and PI ﬂuorescence (y-axis) after 3 h of treatment with P2 at MIC
concentration. l Same as h, but after treatment with 100 μg/mL P2Pro
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Fig. 3 Inclusion body formation and proteostatic collapse. a Growth curve of E. coli BL21-overexpressing p53CD (red) and control in the presence (green) or
absence (blue) of P2 (average and SD of three replicates). p53CD bacterial growth in the presence of 0.4mM IPTG. b Colony formation by E. coli BL21
p53CD-overexpressing bacteria. The bottom and top of the box are the ﬁrst and third quartiles, and the band inside the box represents the median. The
whiskers are drawn using Tukey’s method and show the extreme values that fall within 1.5 times the interquartile range. c Transmission electron
microscopy image of an inclusion body from P2-treated E. coli O157:H7 (uranyl acetate). d Representative Coomassie blue SDS-PAGE of inclusion bodies
from E. coli BL21-overexpressing p53CD (lane 1), mock (lane 2), and E. coli O157:H7 treated with P2 (lane 4), P2Pro (lane 5), or DMSO (lane 6). Molecular-
weight markers are shown in lanes 3 and 7. e Western blot for dnaK, groEL, tig, and dnaJ of the same samples than that in d. f Fluorescence microscopy
image of E. coli cells stably expressing a ﬂuorescent fusion of DnaK (mCer) treated with P2 at MIC concentration. g Growth inhibition of cells treated with
P2 with/without erythromycin (Erm, 100 μg/mL, average and SD of three replicates). h Percent of colony-forming units after treating bacterial KO strains
(KEIO) for 1 h with P2 at its MIC concentration. i Percent of colony-forming units of chaperone-overexpressing E. coli strains treated by P2 peptide at MIC
concentration for 1 h. Signiﬁcant differences from the WT are calculated using ordinary one-way ANOVA and Dunnett’s multiple-comparison test.
Statistical signiﬁcance is indicated as follows: **P≤ 0.01, ***P≤ 0.001, ****P≤ 0.0001
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O157:H7 and p53CD-overexpressing E. coli BL21, but not in
untreated bacteria, suggesting a common molecular machinery
associated with IB formation. In the p53CD IBs, the band cor-
responding to the molecular weight of p53CD and western blot is
clearly visible using the p53 mouse monoclonal antibody pAb240
that recognizes a linear epitope located in the p53CD construct25
(Supplementary Fig. 6). Among the proteins trapped in both
types of IBs, a number of molecular chaperones that are known to
occur in IBs26 could be detected, including the bacterial heat
shock protein 70 (Hsp70) homolog DnaK, the Hsp60 chaperonin
GroEL, the ribosome-associated chaperone trigger factor (TF),
and the bacterial Hsp40 DnaJ (Fig. 3e). The polar localization of a
ﬂuorescently traceable DnaK-mCerulean3 fusion protein (the
latter moiety comprising a blue ﬂuorescent protein) in E. coli K-
12 MG1655 cells exposed to P2 conﬁrms the association of DnaK
with IBs (Fig. 3f).
We then investigated the Coomassie-stained SDS-PAGEs of
IBs isolated both from E. coli O157:H7 and BL21:DE3 upon
treatment with the remaining active and inactive peptides,
which showed a similar high-intensity pattern of IB-associated
proteins for the bactericidal peptides, which was absent or much
reduced in the inactive peptides (Supplementary Fig. 7). So, when
peptides with redundant APRs successfully induce aggregation in
the cell, the process is bactericidal, but when a similar degree of
aggregation is caused by the overexpression of a protein that is
alien to this strain, it is not signiﬁcantly toxic. These observations
show that any toxicity that is associated with IB formation
depends on the proteins that are aggregating into the IBs: a
heterologous protein that aggregates does not represent a loss of
an essential cellular function, and is hence not likely to be toxic.
On the other hand, the simultaneous aggregation of many of the
bacterial cell’s own proteins would eventually be expected to
accumulate such high and pleiotropic levels of loss of function
that cellular viability is ultimately irreversibly impaired. As a
conﬁrmation, we generated a tandem peptide that follows our
design pattern, but that instead of a bacterial fragment contains
an APR from p53CD and indeed found this not to be toxic to E.
coli (Supplementary Note 4, Supplementary Figs. 7 and 8). This
shows that aggregating peptides of this design are not toxic per se,
but that their bactericidal effect depends on the induction of the
aggregation of cellular proteins.
Cotranslational loss of protein homeostasis. To gain more
insight into the speciﬁc composition of IBs associated with the
bactericidal activity of P2, we performed MS proteomic analysis.
To achieve the highest possible coverage, we combined shotgun
analysis of the entire IB samples with samples obtained from
sectioning SDS-PAGE gels of P2-induced IBs into ﬁve equal
sections and analyzed the protein composition of each by MS. We
analyzed six independent biological repeats and considered them
as hit proteins that were detected with a conﬁdence of 99% in at
least two of the six samples (Supplementary Data 1).
This analysis showed that, in agreement with the western blot,
a wide range of chaperones can also be detected in the MS data.
This included the cotranslational TF, the chaperonin system
groEL/groES, the Hsp70 system dnaK/dnaJ/grpE, the hsp90
homolog htpG, and the small Hsp ibpA, as well as the proteases
lon and clpX/clpP/clpA (Supplementary Data 1). In total, 541
proteins were detected in the P2-induced IBs, suggesting that the
bactericidal impact of P2 treatment corresponds to an extensive
proteome-wide aggregation of proteins, in line with our initial
design that aimed at inducing the collapse of protein homeostasis
by aggregation of multiple proteins. Apart from the chaperones,
the IBs were strongly enriched in ribosomal proteins (NCBI
DAVID27, 47 genes, enrichment score of 26.12, Benjamini P value
< 10−98), indicating that protein aggregation in response to P2
may occur cotranslationally. To verify this hypothesis, we
measured the MBC value of P2 in the presence of the macrolide
antibiotic erythromycin, which is a bacteriostatic drug that acts by
blocking the polypeptide exit channel in the ribosome. We
observed a marked desensitization of bacteria (E. coli O157)
(MBC > 100 μg/mL) to P2 after pretreating the cells with 100 μg/
mL erythromycin for 2 h to block translation during peptide
exposure, strongly supporting cotranslational induction of
protein aggregation by P2 (Fig. 3g). In line with this, we observed
by ﬂuorescence-activated cell sorting (FACS) that there was no
buildup of pFTAA staining in the P2-treated bacteria in the
presence of erythromycin (Supplementary Fig. 9), even though
the uptake of FITC-P2 was not impaired by the presence of the
ribosome inhibitor (Supplementary Fig. 10). These data show that
in the absence of protein translation, there is no induction of
protein aggregation and that this eliminates the bactericidal
effect, again showing that the peptide needs to induce protein
Table 2 MIC of P2 for chaperone deletion strains
Gene deletion MIC (μg/mL) Protein name Description
KEIO WT 12
Δ clpP 12 ClpP Proteolytic subunit of the Clp protease
Δ clpA 12 ClpA Substrate-specifying adapter for the Clp protease
Δ clpS 12 ClpS Speciﬁcity adapter for the Clp protease (binds to and modulates ClpA)
Δ clpX 12 ClpX ATP-binding subunit of the Clp protease
Δ lon 12 Lon ATP-dependent protease, required for suppression of aggregation
Δ sulA 12 SulA Suppressor of Lon
Δ clpB 12 ClpB Disaggregase of the Hsp100 family
Δ dnaK 6 DnaK Folding chaperone of the Hsp70 family
Δ dnaJ 12 DnaJ Cochaperone to DnaK of the Hsp40 family
Δ grpE n/a GrpE Nucleotide exchange factor for DnaK
Δ htpG 12 Folding chaperone of the Hsp90 family
Δ groL 12 GroEL Folding chaperone of the Hsp60 family
Δ groS n/a GroES Cochaperone of Hsp60, of the Hsp10 family
Δ hslO 12 Hsp33 Oxidative stress-induced holdase
Δ hchA 6 Hsp31 Heat-dependent and temperature-stress-dependent holdase
Δ ibpA 12 IbpA Small Hsp of the α-crystallin family
Δ ibpB 12 ibpB Small Hsp of the α-crystallin family
Δ tig 12 Trigger factor Cotranslational folding chaperone, ribosome-associated
MIC minimum inhibitory concentration, WTwild type, Hsp heat shock protein
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aggregation in the bacteria to mediate cell death. The data in
Supplementary Fig. 9 additionally demonstrate that the contribu-
tion of P2 itself to the pFTAA staining is small compared to the
bacterial proteins that aggregate in the IBs, meaning that the lack
of pFTAA staining in cells treated with P2Pro (Fig. 2l) really
comes from the failure of this peptide to induce aggregation of
bacterial proteins. In combination, the effect of erythromycin on
P2 and the comparison of P2 with P2Pro establish a causal link
between cotranslational induction of the aggregation of many
bacterial proteins and the bactericidal effect of P2. Moreover, we
could detect eight proteins that contain a sequence fragment
similar to the APR of P2, including the HcaB protein from which
the sequence was derived, and could integrate the other proteins
in the IBs as nodes in an aggregation network connected by
sequence-speciﬁc coaggregation edges (Supplementary Note 5,
Supplementary Table 3, Supplementary Figs. 11, 12, 13, 14, and
Supplementary Data 1).
If the bactericidal effect of P2 is indeed mediated by a loss of
protein homeostasis, the cellular chaperone machinery would be
expected to counteract or limit the effect of the peptide. In order
to evaluate this, we determined the effect of P2 on 18 gene
deletion strains for major bacterial chaperones and proteases in
the E. coli K-12 BW25113 strain (taken from the KEIO
collection28) and found that from the individual knockouts of
the principal proteostatic components of E. coli, only the hsp70
dnaK and the small Hsp, hsp31, had a mild effect on the MIC
value of P2 (Table 2). To ensure that this effect was not due to the
reduced overall viability of the dnaK deletion strain, we also
tested the MIC value at 30 °C and obtained the same result (MIC
= 6 μg/mL). This conﬁrms that the direct inhibition of chaper-
ones and proteases is not the principal mechanism of action of
P2. However, in several of the chaperone or protease deletion
strains, the percent of bacterial cell survival after 1 h was
signiﬁcantly decreased for several deletion strains compared to
the wild-type strain (Fig. 3h), showing that cell killing occurred
much faster in the absence of certain chaperones. The deletion
strains with the strongest effect largely matched those found in
the IBs by MS, including those of the cotranslationally acting
chaperones TF (tig), dnaK (Hsp70 family), and its cochaperone
dnaJ, as well as the small Hsps hchA (Hsp31), hslO (Hsp33), and
ipbA (α-crystallin family). The disaggregase clpB and the
aggregation-controlling protease lon also had strong effects. A
similar picture emerged when we analyzed the sensitivity of E. coli
BL21 after overexpression of selected chaperones: there was no
effect on the MIC values, but the cell killing was slowed down
compared to the wild-type strain in this experiment when the
groEL/ES and dnaK/J/grpE systems were expressed in combina-
tion (Fig. 3i & Table 3). This demonstrates that the protein
quality control (PQC) machinery temporarily opposes the
aggregation induced by the P2 peptide, but is eventually
overwhelmed and ends up associated to the aggregated proteins
in the IB fraction.
IB composition versus toxicity. To better understand the
importance of the quantity and identity of proteins pulled into
aggregates in distinguishing between lethal aggregation and
controlled, nontoxic IB formation, we performed a large-scale MS
proteomics experiment, comparing IB composition from control
conditions to those formed upon overexpression of p53CD with
treatment with toxic (P2, P5, and P14) and nontoxic peptides
(P2Pro, P4), as detailed in Supplementary Note 6, Supplementary
Data 2 and 3, and Supplementary Fig. 15. The ﬁrst observation
that stands out in this analysis is that IBs associated with lethal
conditions contain signiﬁcantly more proteins than those asso-
ciated to nontoxic conditions (Supplementary Fig. 16A). A
common core of IBs was deﬁned by identifying a large group of
424 proteins that are present in IBs of untreated, as well as toxic
and nontoxic peptide-treated BL21. This common core appears to
be primarily composed of the molecular machinery required to
mediate and control IB formation, as well as other proteins that
appear to associate to IBs for reasons that are less obvious
(Supplementary Fig. 17A and B). The former category comprises
the molecular chaperones, such as the chaperonin groE, the
bacterial hsp70 dnaK, the disaggregase clpB, the cotranslational
foldase TF, and, to a lesser extent, the bacterial Hsp90 htpG
among others (Supplementary Fig. 18).
All structural constituents of the ribosome and other elements
involved in the control of protein translation also commonly
dominate the formation of IBs irrespective of the peptide
treatment (Supplementary Fig. 17C and D). However, in addition
to this common core of proteins, each IB contains an additional
set of polypeptides speciﬁcally associated to each condition
(Supplementary Fig. 14B). Of all the samples, the IBs resulting
from the overexpression of the p53CD protein contain the
smallest number of additional proteins (eight proteins, including
p53CD). The p53CD polypeptide strongly dominates the
composition of the IBs from the overexpressing cells (Fig. 3d).
This indicates that the heterologous expression of p53CD leads to
IBs that essentially consist of a large quantity of the overexpressed
protein, plus the proteins typically found in the IB fraction across
conditions. This makes sense in the context of recombinant
protein puriﬁcation from such IBs and explains the lack of
toxicity observed under these conditions. It is also in line with the
notion that p53CD aggregation constitutes a proteostatic stress
that, contrary to P2, does not cause a proteostatic collapse and is
not lethal to the bacterial cell. In the IBs from nonlethal
conditions, including p53CD, P2Pro, and P4, we detect fewer
additional proteins than in the IBs from lethal conditions
(Supplementary Fig. 16B). Moreover, these additional proteins
in the nonlethal IBs are often from the same functional categories
as the GO enrichments associated to the common core,
suggesting that the formation of nontoxic IBs is a more controlled
process than those formed in the lethal conditions (Supplemen-
tary Fig. 17). In the IBs from lethal conditions combined (P2, P5,
and P14), we found between 47 and 154 bacterial proteins in
addition to the typical IB proteins found in the common core,
with contrasting molecular functions (Supplementary Fig. 17C),
showing what a devastating impact these peptides have on the
PQC, and conﬁrming the notion that peptides containing
redundant APRs cause widespread protein aggregation. The
isolated genetic deletion of many of these elements individually
completely impairs viability. So, it may be unsurprising that the
accumulated loss of many of these proteins is lethal, even if the
knockdown of each individual protein is likely to be less complete
than in the genetic deletion.
In conclusion, the MS data presented here are in good
agreement with the notion that our peptides cause a pleiotropic
and accumulated loss of function to protein aggregation that is
eventually lethal.
Table 3 MIC of P2 after chaperone overexpression in BL21
Plasmid Overexpressed chaperone(s) MIC (μg/mL)
pG-KJE8 dnaK-dnaJ-grpE groES-groEL 25
pGro7 groES-groEL 25
pKJE7 dnaK-dnaJ-grpE 25
pG-Tf2 groES-groEL-tig 25
pTf16 tig 25
wt — 25
MIC minimum inhibitory concentration
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Exploiting redundant APRs in vivo. Since bioinformatics ana-
lysis showed that our peptides differ markedly from existing
antimicrobial peptides (Supplementary Note 7), we wanted to
know if the induction of proteostatic collapse mediated by P2
could be exploited as an antimicrobial peptide.
We tested the uptake of P2 in other bacterial strains and found
peptide uptake in several different bacterial species (Supplemen-
tary Fig. 19). Then, we proceeded to test the activity of P2 against
17 clinical isolates of E. coli and 15 of A. baumannii, which
displayed a varying spectrum of resistance against well-
established antibiotics (Supplementary Table 4). We found P2
to be effective on 16 out of 17 of the tested E. coli strains and 14
out of 15 of the Acinetobacter strains, including those resistant to
the last-resort carbapenems. As a ﬁrst indication of speciﬁcity of
the peptides, we demonstrated that there were no hemolytic-to-
human erythrocytes (Fig. 4a), suggesting that the bactericidal
effect of P2 is not the result of a generic toxicity. This was further
conﬁrmed by CellTiter Blue (Fig. 4b) and lactate dehydrogenase
(LDH) release (Fig. 4c) assays to assess the cytotoxicity of the
peptide for HeLa cells. The speciﬁcity of P2 for E. coli O157:H7
was estimated by determining the concentration at which
bacterial growth is 50% inhibited (IC50= 1.5 μg/mL) and
compared to the concentration at which the peptide induces
50% lysis of human erythrocytes (LC50= 1,100 μg/mL), yielding
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an apparent therapeutic ratio of 730. In order to test the in vivo
potential of P2, we treated a coculture of mammalian (HeLa) cells
and E. coli O157:H7 with P2 and observed the preferential
accumulation of P2 in bacteria but not in mammalian cells
(Fig. 4d). In addition, we tested the cross-reactivity of P2
aggregation with known disease-associated amyloidogenic pep-
tides in vitro by spiking P2 into freshly dissolved preparations of
the human Alzheimer β (Aβ) peptide or the human islet amyloid
polypeptide and did not observe an increase of the rate of
aggregation of these peptides (Fig. 4e, f), showing that the peptide
is not a general inducer of protein aggregation. We did, however,
observe a delay in the aggregation onset of the Aβ peptide,
suggesting that a transient interaction did take place (Fig. 4e).
Finally, we found that P2 incubated in 25 or 50% human serum
for 2 h was still able to inhibit bacterial growth at 25 and 50 μg/
mL (Fig. 4g). Moreover, initial experiments outlined in
Supplementary Note 8 showed that mice tolerated P2 treatments
well (Supplementary Tables 5, 6 and Supplementary Figs. 20, 21,
and 22 and Fig. 4h).
Based on these observations, we tested the antibacterial efﬁcacy
of the P2 in a mouse bladder infection model. In this model, an
inoculum of 50 μL of a 108 CFU/mL suspension of E. coli O157:
H7 was delivered via the urethra to the bladder of healthy Swiss
mice. One hour post infection, we administered a single injection
of P2 at 10 mg/kg, either via the urethra (denoted at UT, n= 15)
or intraperitoneally (denoted as IP, n= 15). As a positive control,
we included ampicillin treatment, which was administered orally
(20 mg/kg), while P2Pro was administered urethrally (10 mg/kg)
and buffer treatment served as negative controls. Twenty-four
hours after treatment, the animals were killed and the bacterial
titer in kidney, colon, bladder, and ureter was determined by
plating the macerated tissue (Fig. 4i–l). These experiments
revealed a signiﬁcant reduction of the bacterial titer in the
different organs of P2-treated animals (P value <10−4 compared
to buffer control and P value <10−4 compared to nonaggregating
P2Pro control, analysis of variance (ANOVA) with Tukey's
posttest). The log-fold reduction of the average bacterial load
ranged from 2.3 in the ureter to 3.0 in the kidney after IP delivery
and from 2.6 in the colon to 3.1 in the ureter upon UT delivery.
The effect was comparable to orally dosed ampicillin (20 mg/kg)
in the ureter, but P2 treatment was better in reduction of the
bacterial load in the other tissues, ranging from 1.48 log-fold in
the colon to 2.0 log-fold in the bladder. These results clearly
indicate that the antimicrobial activity of P2 against E. coli is
maintained in vivo.
Discussion
The emergence of multidrug-resistant Gram-negative infections
represents one of the major healthcare challenges of the coming
decade(s), but alternative treatment options are currently not
available29. We present here a class of peptides with a strong
bactericidal effect against multidrug-resistant clinical isolates of E.
coli and A. baumannii, both in vitro and in a bladder infection
model in the mouse. These peptides act by inducing widespread
protein aggregation in these bacteria, eventually causing cell death
by overcoming the bacterial protein homeostasis system. Protein
misfolding and aggregation are relatively common events under
normal physiological conditions and are increased under condi-
tions of stress such as heat shock, but the PQC controls the
process and avoids that it degenerates. For example, upon
recombinant production of heterologous proteins in bacteria, the
aggregating protein is stored into IBs, and little or no toxicity is
associated. However, human protein aggregation diseases
revealed that when stress is too intense or sustained, the capacity
of the PQC to control misfolding events is exceeded, resulting in
protein aggregation and IB formation30–32. Here, we exploit this
concept to induce toxic protein aggregation in the Gram-negative
bacteria by using aggregation-prone peptides whose sequence is
based on aggregation protein sequences that occur in many
bacterial proteins. The idea is that these peptides will cause
aggregation of many different bacterial proteins that share this
short seven-amino-acid stretch. The pleiotropic loss of function
of many proteins at the same time eventually overcomes the
capacity of the PQC to correct the problem and the viability of
the cell is negatively affected. Because the approach disrupts an
essential process by targeting many different proteins, we hope
that the emergence of resistance may be inherently more difﬁcult
for the bacteria than for single-target approaches. Indeed, repe-
ated passaging of bacteria on sublethal concentrations of the
active peptides for a period of 36 days did not result in the
development of resistance contrary to the control of the antibiotic
ampicillin.
Our method is based on the notion that protein aggregation is
a sequence-speciﬁc process that is nucleated by, and can thus be
induced with, short APRs within a protein that self-assemble to
form aggregates8,33–35. Most proteins possess at least one APR in
their sequence. We recently demonstrated, however, that most of
these aggregation-prone sequences are unique in a proteome7,10.
In other words, when a protein aggregates, it will generally only
aggregate with identical proteins. We previously exploited the fact
that aggregation is sequence speciﬁc and that most aggregating
sequences are sparse in a proteome to induce speciﬁc protein
knockdown of target proteins in plants15 and mammalian cells23,
or to achieve protein detection in western blot using protein-
speciﬁc APRs7. During these exercises, we realized, however, that
a minority of aggregation-prone sequences are found within
several and sometimes many proteins. By the same mechanistic
reasoning, this suggests that a minority of proteins will, when
Fig. 4 Cross-seeding and in vivo activity. a Concentration-dependent hemolysis of human erythrocytes by selected peptides (average and SD of three
replicates) shown as percent of hemolysis compared to 1% Triton. b, c Cytoxicity of P2 (black bars) and P2Pro (gray) to human HeLa cells measured using
the CellTiter Blue assay (b) (average and SD of three replicates) and the lactate dehydrogenase (LDH) release assay (average and SD of three replicates),
represented as percentage of cell survival compared to control. d Fluorescence micrography of HeLa cells mixed with E. coli O157:H7, treated with FITC-P2
(green channel). Blue is DAPI (4',6-diamidino-2-phenylindole), red is CellMask Deep Red. e Aggregation kinetics of the Alzheimer β (Aβ) peptide at 50 µM
with/without P2, monitored using thioﬂavin-T ﬂuorescence (average and s.d. of three replicates). f Same as b for human islet amyloid polypeptide (IAPP).
g Inhibitory effect of 5, 25, and 50 µg/mL P2 on bacterial growth in the presence of human blood serum (25 or 50%; average and SD of three replicates). h
ELISA on immobilized FITC-P2 using blood serum of mice treated for 18 days with 30mg/kg P2. An anti-FITC antibody was used as a positive control for
peptide immobilization (three replicates from three mice). i–l Antibacterial efﬁcacy of P2 in a mouse model of bladder infection. The bacterial load of mice
infected with E. coli O157:H7 transurethrally was determined after treatment with P2 (P2 administered urethrally (P2 UT) or intraperitoneally (P2 IP)) and
controls (ampicillin administered orally (Amp.oral), buffer (mock), and P2Pro administered urethrally (P2Pro2.UT)) in i kidney, j colon, k bladder, and l
ureter. Each treatment group consisted of 15 animals. Bacterial loads are expressed as log10(CFU/mL). See text and Methods for more details. Plots i–l
show individual measurements, as well as mean and s.d. Signiﬁcant differences were calculated using ANOVA with Tukey's post hoc test. Statistical
signiﬁcance is indicated as follows: ***P≤ 0.001
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aggregating, induce the aggregation of several and even many
other proteins. This also suggests that most proteomes possess
proteostatic weaknesses that might constitute hot spots for pro-
teostatic collapse under conditions of stress.
From a small screen of 75 frequently occurring APRs from E.
coli, we found that more than half had antibacterial activity at 25
μg/mL, showing that these APRs are a particularly rich source of
APRs that can induce widespread protein aggregation. For several
of these peptides, we demonstrated that they indeed enter cells
and cause protein aggregation in the form of IBs that contain
hundreds of bacterial proteins. Taken together, our ﬁndings
suggest that redundant APRs (which are a minority of the APRs
in the E. coli proteome) indeed represent hot spots for proteo-
static collapse, the aggregation of which is so widespread that it is
bactericidal. This approach could therefore also represent an
interesting paradigm to be explored for the development of a new
class of antibiotics.
Methods
All primer sequences are listed in Supplementary Table 7.
Bioinformatics analysis. Protein sequences for various bacterial strains were
obtained from UniProt36, and redundance was removed using the cd-hit algo-
rithm37. We employed the software algorithm TANGO to idenitify APRs across
this work, using a TANGO score of 5 per residue as the lower threshold. This was
previously shown to yield a Mathews correlation coefﬁcient of 0.9238 between
experimentally determined and predicted aggregation. The parameter conﬁgura-
tion TANGO was temperature at 298 K, pH at 7.5, and ionic strength at 0.10M.
Peptide synthesis. Initial peptide screens were obtained as microscale peptide sets
(200-nmol scale) from JPT (Berlin, Germany). Peptide hits were reordered from
several vendors (Genscript, Shanghai, China and PepScan, Lelystad, The Nether-
lands) at higher purity (>90%) and were also produced in-house using the Intavis
Multipep RSi automated synthesizer. In-house HPLC puriﬁcation was performed
with a Zorbax SB-C3 semi-preparative column (Agilent, USA) installed on a
Prominence HPLC (Shimadzu, Japan). Peptides were freeze-dried and stored at
−20 °C prior to use.
Bacterial strains and growth conditions. Bacterial cells were collected from
different human clinical samples, and from the University Hospital Leuven-
Gasthuisberg.
Gram-negative bacterial strains were cultivated in Luria-Bertani (LB) broth
(Difco) and Gram-positive bacteria strains were grown in a rich medium, brain
heart infusion broth (Difco, Sparks, MD, USA) at 37 °C. Whenever required
growth media
were supplemented with appropriate antibiotic to the medium or plates (ampicillin
25 μg/mL, erythromycin 100 μg/mL, chloramphenicol 20 μg/mL, kanamycin 30 μg/
mL, L-arabinose 0.5 mg/mL, and tetracycline 2ng/mL). Escherichia coli DH5α
(Thermo Fisher Scientiﬁc) was used for cloning and plasmid ampliﬁcation. For
selection of antibiotic resistance colonies, E. coli carrying plasmids was grown in LB
medium supplemented with the relevant antibiotic. Bacterial CFU counting was
done on blood agar plates (BD
Biosciences) or LB agar plates. Species identiﬁcation and antibiograms for all
clinical isolates were performed using MALDI-Tof and VITEK® 2 automated
system (bioMérieux).
MIC determination. The MICs of active peptides were determined via the Broth
microdilution assay according to the EUCAST guideline, which was performed in
96-well polystyrene ﬂat bottom microtiter plates (BD Biosciences). Brieﬂy, a single
colony was inoculated into 5 mL LB medium and grown to the end-exponential
growth phase in a shaking incubator at 37 °C. Cultures were subsequently diluted
to an OD600 (optical density) of 0.002 (1 × 108 CFU/mL) in fresh LB medium. One
hundred microliters of LB medium with different concentration of peptides ran-
ging from 100 to 0.75 μg/mL were serially diluted to the sterile 96-well plate (at
least three wells in each plate). Afterwards, 100 μL of the diluted bacteria were
pipetted into 96-well plates containing different concentration of peptides. In each
plate, the grown bacteria with the maximum concentration of carrier and medium
were considered as positive and negative controls, respectively. Thereafter, 96-well
plates were statically incubated overnight at 37 °C to allow bacterial growth. OD
was measured at 590 nm for 1 s using a multipurpose ultraviolet–visible plate
reader, and the absorbance of the growth bacteria was measured using a Perkin
Elmer spectrophotometer (1420 Multilabel Counter Victor 3).
Antibody and antibiotic product codes. The antibodies and antibiotic product
codes used are as follows: anti-CLPB (Aviva, catalog# ARP53790_P050) 0.5 μg/mL,
anti-DnaK (Aviva, catalog# OAED00201) 1 μg/mL, anti-TF (Clontech, catalog#
M201) 2 μg/mL, anti-groEL (Abcam, catalog# ab82592) 1 μg/mL, and anti-DnaJ
(Enzo Life Sciences, catalog# ADI-SPA-410-D) 0.5 μg/mL. Ampicillin sodium, CAS
number 69-52-3 (Duchefa Biochemie, catalog# A0104), erythromycin, CAS num-
ber 114-07-8 (Sigma-Aldrich, catalog# E5389), chloramphenicol, CAS number 56-
75-7 (Duchefa Biochemie), and kanamycin CAS number 56-75-7 (Duchefa
Biochemie).
Biophysical characterization. DLS measurements were performed at a ambient
temperature using a DynaPro DLS plate reader (Wyatt, Santa Barbara, CA, USA),
employing a 830 nm laser at 90° angle in ﬂat-bottomed 96-well microclear plates
(Greiner, Frickenhausen, Germany). Data were recorded in 10 s reads and 40
readings were averaged. All calculations of hydrodynamic radius were performed
using the Wyatt Dynamics software. For attenuated total reﬂection Fourier
transform infrared spectroscopy (ATR-FTIR), we used the Bruker Tensor 27
infrared spectrophotometer and its Bio-ATR II accessory. We used a spectral
resolution of 4 cm−1 and recorded spectra in the 900–3,500 cm−1 interval, aver-
aging over 120 data acquisitions while purging the instrument with dry air.
Atmospheric interference corrections and baseline subtractions were carried out
before the spectra were rescaled in the amide II area (1,500–1,600 cm−1). For TEM,
samples were adsorbed to carbon-coated Formvar 400-mesh copper grids (Agar
Scientiﬁc) for 1 min, washed, and stained with 1% (wt/vol) uranyl acetate. Electron
micrographs were recorded using a JEOL JEM-1400 microscope (JEOL, Tokyo,
Japan) at 80 kV.
Time-killing kinetic assay. The time-killing kinetic study of the peptides was
carried out to assess the killing rate of the bacteria at enough exposure time points.
This study was done according to standard guide for assessment of antimicrobial
activity using time-killing kinetic procedure. Selection of agent concentrations was
guided by MIC endpoints.
Brieﬂy, 20 μL of frozen cultures of E. coli O157: H7 were inoculated into 5 mL
LB and grown to the end-exponential growth phase in a shaking incubator at 37 °C.
Cultures were subsequently diluted to an OD600= 0.002 (1 × 108 CFU/mL) in fresh
LB medium. To evaluate the effect of aggregators over time, bacterial cells were
subjected to a concentration of different peptides at the MIC value for different
periods of time (5 min, 10 min, 30 min, 1 h, till 6 h). After the deﬁned contact
period, 50 μL of each culture was serially diluted and plated on blood agar plates.
Plates were incubated overnight at 37 °C without shaking. The number of viable
organisms was counted as CFU/mL.
Multistep resistance development study. The ability of the target strains to
develop resistance to active compounds was evaluated by repeated subculturing in
the presence of the half-MIC value of the active peptides over 30 days. Brieﬂy, E.
coli O157 cultures were grown in LB medium, the OD of bacteria was then adjusted
to an OD600 of 0.002 (equivalent to 1 × 108 CFU/mL). Bacterial cells were treated
by the aggregator at half-MIC concentration; after a 24 h incubation period, the
MIC’s were tested by a microdilution assay according to the EUCAST guideline
and the bacteria were re-cultured in the presence of the half-MIC value of the
respective aggregator. Ampicillin was used as the positive control in this
experiment.
Scanning electron microscopy. For SEM, E. coli O157 or BL21 bacterial cells in
end-exponential growth phase were diluted to a density of 108 CFU/mL and treated
with supra-MIC concentrations of peptides. After 2 h treatment, bacterial cells were
trapped by nitrocellulose membrane ﬁlters (0.1 μm CAS 900470.0 Ref. VCWP0/
300) and then were ﬁxed with 2% glutaraldehyde for 1 h. One percent of 1%
osmium tetroxide (OsO4) was used as postﬁxation in 0.1 M sodium cacodylate
buffer for 1 h. Samples were washed three times with cacodylate buffer (0.1 M
sodium cacodylate) for 10 min at room temperature (RT). The samples were
dehydrated with a graded ethanol series (50, 70, 96, and 100% alcohol). After the
dehydration step, samples were dried by hexamethyldisilazane for 1 h and mounted
on the specimen stubs and sputter coated with gold. An SEM-FEG (ﬁeld emission
guns) microscope (JEOL JSM 6700F) with an accelerating voltage of 30 kV was
used.
Cross-section TEM. Escherichia coli at the end-exponential growth phase were
washed twice and diluted with physiological water and subsequently treated with
either MIC value of speciﬁc aggregator peptides or buffer for 2 h (Control group) at
37 °C. After 2 h, bacterial cells were centrifuged at 4,000 × g for 4 min and pellets
were ﬁxed by 2.5% glutaraldehyde in 0.1 M Na-cacodylate buffer, pH= 7.2–7.4
(+2.5 mM CaCl2+ 1 mM MgCl2), for 1 h. Then, the pellets were washed with
cacodylate buffer, re-suspended in 1.5% low melting point agarose (Sigma A4018)
in cacodylate buffer (40 °C), and centrifuged at 4,000 × g for 4 min. The centrifuge
tubes were placed on ice for 15 min, after which the tips containing the pellets were
cut-off and the pellets were removed in a drop of cacodylate buffer. Pellets were cut
into 1 mm³ cubes (4 °C), post-ﬁxed with 1% OsO4 in distilled water for 2 h, and
washed twice with distilled water. Thereupon, the samples were dehydrated in a
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graded ethanol series (30, 50, 70, 90, and 100%) for 5 min in each step at 4 °C while
slowly rotating (ethanol 100%, repeated three times). Finally, cells were treated with
propylene oxide (Sigma CAS number: 75-56-9) twice for 15 min at 4 °C, inﬁltrated
with a 1:1 mixture of epoxy resin and propylene oxide (60 min at 4 °C, slowly
rotating), and subsequently left in a mixture of 2:1 epoxy resin and propylene oxide
overnight under a fume hood without caps. The next morning, samples were
placed in 100% fresh epoxy resin, embedded in BEEM capsules in the evening, and
polymerized for 2 days in an oven at 60 °C. Ultrathin sections were cut with a Leica
ultracut UCT ultramicrotome and observed in a JEOL JEM-1400 TEM operated at
80 kV and equipped with an Olympus Quemesa 11Mpxl camera.
In vitro hemolytic activity test. The hemolytic activities of peptides were deter-
mined by hemolysis against human erythrocytes. Pooled fresh blood was obtained
from healthy volunteers (Red Cross Flanders) and erythrocytes were collected by
centrifugation 1,000 × g for 5 min (anticoagulated by EDTAK). The pellet was
washed three times with phosphate-buffered saline (PBS) and was diluted to a
concentration of 8% in PBS. One hundred microliters of 8% red blood cells
solution was mixed with 100 μL of serial dilutions of peptides in PBS buffer in 96-
well plates (BD Biosciences). The reaction mixtures were incubated for 1 h at 37 °C.
Thereupon, the plate was centrifuged for 10 min at 1,000 × g and 100 μL of
supernatant was transferred to a sterilized 96-well plate (BD Biosciences, ﬂat
bottom). The release of hemoglobin was determined by measuring the absorbance
of the supernatant at 405 nm. The hemolytic activity was determined as the
minimal peptide concentration that caused hemolysis (minimal hemolytic con-
centration). Erythrocytes in 1% Triton and maximum used concentration of vehicle
were used as the control of 100 and 0% hemolysis, respectively.
In vitro mammalian cytotoxicity. Mammalian cytotoxicity was measured using
the LDH release (Roche, Mannheim, Germany) and CellTiter Blue (Promega)
methods. Brieﬂy, HeLa cells (the human cervix epitheloid carcinoma cell line HeLa
was obtained from the European Collection of Authenticated Cell Cultures
(ECACC 93021013)) were seeded in 96-well round bottom plates at a concentra-
tion of 3 × 105 cells/mL in Dulbecco’s modiﬁed Eagle’s medium and treated by
different concentrations of peptides. Cells treated with 1% Triton™ X-100 and
vehicle were considered as positive and negative controls, respectively. Microplates
were incubated at 37 °C with 5% CO2 and 90% humidity for 4 h. The micro-plate
was centrifuged at 200 × g for 10 min. One hundred microliters of supernatant was
transferred to a clear 96-well ﬂat bottom microplates. In order to determine LDH
activity in the supernatants, 100 μl reaction mix (catalyst and dye solution) was
added to each well and incubated for 30 min at RT in the dark and the LDH
reaction was stopped by adding 100 μL of the stop solution. The absorbance of the
samples was measured at 490 nm. The cell viability was calculated using the for-
mula: (exp.value− negative control value)/(positive control value− negative con-
trol value)×100. The amount of absorbance is proportional to the number of living
cells and corresponds to the cells’ metabolic activity. Cell lines were regularly tested
for Mycoplasma contamination.
Expression of HcaB in E. coli ATCC 25922 strain. The coding regions of E. coli
O157 HcaB were ampliﬁed using hcaB-speciﬁc primers (5′-ATGTCGA-
CATGAGCGATCTGCATAACGA-3′ and 5′-ATGTCGA-
CATGGAGCGATTTATCGAAGAAGGC-3′, 5′-
ATCCCGGGTTAAAGATCCAACCCAGCCG-34′) containing
SalI and SmaI restriction sites for cloning purposes. Two truncate versions of the
gene, one with the targeted gene part, APR, and the other one without the target
region were designed. For genomic DNA
(gDNA) of bacteria E. coli O157 strain, a clinical isolate was used as a template.
The amplicons were ligated into SalI/SmaI-digested pCN68 E. coli– Staphylococcus
shuttle vectors yielding different truncated version of pCN-hcaB. In this plasmid,
PblaZ is the promoter. Ampicillin (25 μg/mL) or erythromycin (100 μg/mL) was
used as the selection markers. Correctness of cloning was conﬁrmed ﬁrst by
restriction enzyme digestion, colony PCR, and nucleotide sequence analysis of the
insert and then by sequencing.
Knockout and co-expression chaperone strains. Knockout chaperon strains
were purchased from Dharmacon E. coli Keio knockout collection, which contains
a set of single-gene deletion mutants for chaperone E. coli K-12 genes. Each deleted
gene has been replaced with a kanamycin (30 μg/ mL) resistance cassette.
Chaperone co-expression plasmids were purchased from Takara set (catalog#
3340), which consists of ﬁve different plasmids that contain chaperone plasmids
developed by HSP Research Institute Inc. Plasmids were transformed into
competent E. coli BL21. The co-expression chaperone strains are chloramphenicol
selective of chaperone plasmid (20 μg/mL), and chaperone inducer depending on
the chaperone plasmid used. pG-KJE8 (DnaK-dnaJ-grpE araB groES-groEL)
induced by L-arabinose (0.5 mg/mL), tetracycline (1–5 ng/mL), pGro7 (groES-
groEL) induced by L-arabinose (0.5 mg/mL), pKJE7 (dnaK-dnaJ-grpE) induced by
L-arabinose (0.5 mg/mL), pG-Tf2 (groES-groEL-tig) induced by tetracycline
(1–5 ng/mL), and pTf16 (tig) induced by L-arabinose (0.5 mg/mL).
Macrolide and peptide interaction. To evaluate the effect of peptides in the
presence of erythromycin, E. coli O157 was grown in 5 mL of LB. Exponential-
phase cultures were then diluted to 108 cells/mL. Bacterial cells were treated with
erythromycin at the concentration of 100 μg/mL for 3 h to stop growing at 37 °C,
without shaking. Different concentrations of peptides (from 100 to 0.75 μg/mL) or
buffer were plated in 96-well plates with at least three replicate wells (50 μL). Fifty
microliters of erythromycin-treated bacteria were added to each well and 96-well
plate was incubated for 2 h at 37 °C. After 2 h, bacterial cells were serially diluted
and cultured on blood agar plates. Plates were incubated at 37 °C overnight. The
number of living cells was measured by CFU counting method.
Fluorescence microscopy of co-cultures of bacteria and mammalian cell. For
imaging purposes, human HeLa cells were grown on small-cell-view cellular dish
with glass bottom (Greiner Bio-One GmbH/35 mm Ref: 627860) to form a con-
ﬂuent monolayer. Thereupon, cells were infected with 200 μL of an overnight
culture of E. coli O157 strain with FITC peptide (3 ×MIC) for 24 h. Cells were
stained with CellMask Deep Red plasma membrane dye (Thermo Fisher catalog#
C10046) and 1 μL of NucBlue reagent for 30 min (Invitrogen), and then the
medium was removed and 2 mL paraformaldehyde 4% was added to the plate for
ﬁxation. The plate was incubated for 6 h at RT. The co-cultured cells were washed
at least three times with 1 mL PBS prior to imaging.
Staining with luminescent conjugated oligomers. Two hundred microliters of
end-exponential culture E. coli O157 were washed with PBS for three times, the
bacterial numbers were adjusted to 108 cells, and afterwards, bacteria were treated
with peptides (at MIC) or buffer for 1 to 2 h. After 2 h, cells were treated with LCO
dye (pFTAA; 0.5 μM, ThT; 25 μM) for 90 min. The absorption and emission
spectra were measured from 480 to 600 nm with excitation at 440 nm (20 nm
bandpass).
Flow cytometry analysis of bacteria treated by peptides. Using a double
staining technique with propidium iodide (PI) and FITC peptides, killing rate and
peptide uptake were evaluated in a two-dimensional analysis. Brieﬂy, end-
exponential growth phase E. coli O157 cells (108 CFU/mL) were washed with PBS
and treated with peptides (P2 or Pro2/ FITC labeled) at MIC value for different
time periods. Treated bacteria were again washed with PBS buffer three times. One
microliter of PI (Invitrogen) was added to the bacteria, and after incubation for
5 min, the mixture was aliquoted (500 μL) into FACS tubes. To correlate the
activity of the peptides with cell death, the ﬂuorescence intensity was measured in
two channels using the GalliosTM Flow Cytometer, PI: excitation 536 nm and
emission 617 nm, FITC: excitation 490 nm and emission 525 nm. Heated bacteria
at 90 °C for 10 min were used as PI-positive control.
IB puriﬁcation. Twenty milliliters of overnight culture of bacteria was centrifuged
for 30 min at 4,000 × g and washed by physiological water. Bacterial cells were
treated by peptide at MIC for half killing time; afterwards, the bacterial pellets were
washed with 10 mL buffer A (50 mM HEPES, pH 7.5, 300 mM NaCl, 5 mM β-
mercaptoethanol, 1.0 mM EDTA) and centrifuged at 4 °C for 30 min at 4,000 × g.
The supernatant was discarded and 20 mL of buffer B (buffer A plus 1 μg/mL
leupeptin, 0.1 mg/mL AEBSF (4-(2-aminoethyl)benzenesulfonyl ﬂuoride hydro-
chloride)) was added to the bacterial pellet. In order to break the cells, a Glen
Creston Cell Homogenizer with pressure set to 20,000–25,000 psi was used, and in
addition, the suspensions were sonicated (Branson Digital soniﬁer 50/60 HZ) on
ice with alternating 2 min cycle (15 pulses at 50% power with 30 s pauses on ice,
until completing 2 min total sonication time). The lysed cells were centrifuged at 4 °
C for 30 min at 11,000 × g. The precipitated fraction was afterward re-suspended
with 10 mL buffer D (buffer A plus: 0.8% (V/V) Triton X-100, 0.1% sodium
deoxycholate) and the suspension was sonicated to ensure the pellet is completely
dissolved. This step was repeated three times. Centrifugation was performed at 4 °C
for 30 min at 11,000 × g. Finally, to solubilize IB, the pellet was suspended in 1 mL
of buffer F (50 mM HEPES, pH 7.5, 8.0 M urea) per gram of precipitated fraction.
Peptide activity and stability in the presence of serum. Brieﬂy, the blood was
allowed to clot for 90 min at RT. The blood was then centrifuged at 1,000 × g for
10 min and serum was separated. Serum was diluted into RPMI medium Gibco™
(25 or 50%) and peptides with different concentration of 5, 25, and 50 μg/mL were
added to each well. After 2 h incubation, end-exponential E. coli O157 culture was
washed three times by PBS (7,100 × g, 10 min). The number of bacteria was then
adjusted to 9 × 108 cells in RPMI medium with or without serum. After 2 h
incubation, bacterial cells were serially diluted and were cultured on blood agar
plates. The plates were then incubated at 37 °C overnight. The number of living
bacteria was quantiﬁed as the number of CFU/mL.
HcaB puriﬁcation and antibody production. The coding whole E. coli hcaB gene
(SE2232, Taxonomy ID: 83333) was ampliﬁed using hcaB-speciﬁc primer (5′-
CATATGATGCATCATCACCATCACCACAGCGATCTGCATAACGA-3′ and
5′-CCTAGGTTAAAGATCCAACCCAGCCG-3′) with additional NdeI and BamHI
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restriction site (underlined and italic) for cloning purposes. Anti-6xHis (bold) tag
used as a tag on the recombinant proteins to facilitate protein puriﬁcation.
gDNA of E. coli strain O157 was used as a template. The amplicon was ligated
into NdeI/BamHI-digested pET11C plasmid as a component of a system for
protein expression in E. coli yielding pET-his-hcaB. In this plasmid, T7 RNA
polymerase (highly active constitutive promoter) was the promoter. Ampicillin
was used as the selection marker. All recombinant plasmids were replicated in
E. coli BL21 to have BL21 pET-his-hcaB. The correctness of cloning was
conﬁrmed by restriction enzyme digestion, and nucleotide sequence analysis of the
insert.
Protein was puriﬁed as described previously (Luminy and Cedex 2011). Brieﬂy,
E. coli BL21 pET-his-hcaB was grown in 1 L of LB broth with 100 μg/mL ampicillin
and 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) at 37 °C overnight with
shaking. The cells were harvested (1,700 × g, 10 min, 4 °C) and re-suspended in
25 mL lysis buffer (PBS, pH 7.5, 1 mM β-mercaptoethanol plus 1 tablet protease
inhibitor Mini, EDTA-freelyse). Bacterial cells were lysed using French pressure cell
press (EmulsiFlex-C3 homogenizer) and stirred at 4 °C by adding DnaseI, and
whole proteins were puriﬁed. To get rid of aggregation, we kept the proteins on ice
and then ﬁltered it. HcaB protein puriﬁcation was performed by AKTA FPLC
system, which is a fully automated liquid chromatography system, where HcaB
protein was puriﬁed using HiPrepTM HP 5mL column. Before actual puriﬁcation
run, the AKTA were stripped, charged, and blanked. The puriﬁcation was done by
program in AKTA Xpress. The puriﬁed proteins were collected from different
tubes and the combined fractions were kept at 4 °C. Puriﬁed proteins were checked
by running on the SDS gel.
In order to make polyclonal antibodies, several Swiss mice were immunized
twice IP, in 10 days. The ﬁrst injection was administered with a mixture of HcaB
protein (50 μg per mouse) and complete Freund’s adjuvant (Sigma) (1:1). On day
10, a booster injection (protein and incomplete Freund’s adjuvant (Sigma)) was
given after titration of the antibody by enzyme-linked immunosorbent assay. Then
from the serum, the total immunoglobulin Gs puriﬁed by absorption to a protein G
column (GE Healthcare) according to the manufacturer’s instructions.
Experimental animals. Female Swiss mice of 5 to 8 weeks with uniform weight (20
and 23 g) were used in this study (Harlan, The Netherlands). Mice were housed in
plastic cages, ﬁve mice per cage on softwood granules as bedding. The room was
kept between 21 °C and 25 °C with 12/12 h light–dark cycles. The animals had free
access to water and pelleted rodent food. In order to avoid stress-induced con-
founding factors mice were transferred to the lab 1 week before experimental
manipulation.
In vivo toxicity test. The procedures used in the assays were approved by the local
Animal Ethics Committee and conform to international standards of animal
welfare (Approval P067/2015 of the Ethical Committee of KULeuven). A safe
concentration of peptides of 30 mg/g was used for this experiment. The selected
dose achieved from escalation experiment had no acute adverse effects upon IP
administration.
Brieﬂy, 5–6-week-old Swiss females were divided into three groups (six animals
per group) and administered 30 mg/kg of P2 (group A) or vehicle (physiological
water pH 7.5) (group B) once a day for 18 days via IP injection. During the
treatment period, the clinical, physiological, and behavioral parameters, including
body weight, food and water consumption, body condition score, home cage
activity, and locomotion were constantly monitored and recorded.
Three days after the last administration, animals were anesthetized and blood
was collected using a standard retro-orbital puncture from each animal. Next, the
mice sacriﬁced and underwent complete necropsy with gross examination and
organ weights. The organs (heart, liver, spleen, kidney, bone marrow, brain, lung)
were sampled and immersed in ﬁxative in 4% paraformaldehyde. Formalin-ﬁxed
tissues after dehydration were routinely processed and embedded in parafﬁn blocks
for histopathological examination. Five-micrometer-thick sections taken from
these blocks (Thermo Scientiﬁc Microm HM355S microtome) were then stained
with hematoxylin and eosin (Leica ST5010 Autostainer XL) and evaluated under a
Leica DM 2500 light microscope by a board-certiﬁed veterinary pathologist.
Hematology examination was performed using an automated high-resolution ﬂow
cytometer, Abbott Cell-Dyn 3700.
The urinary tract infection model. Eight-week-old Swiss female mice were used
for the urinary tract infection model as described previously39. Brieﬂy, mice were
anesthetized by IP administration of Nembutal 10% and then with ﬁngers the
bladder of the mouse was massaged and pushed down gently on to expel remaining
urine. Thereafter, the anesthetized mice were inoculated UT with 50 μL of bacterial
suspension slowly (1 × 108 CFU/mL) by the sterile catheter in the bladder over 5 s
in order to avoid vesicoureteral reﬂux through a surgical microscope. We estimated
the sample size as follows: allowing a type I error rate of 0.05, a type II error 0.2,
and estimating the maximum standard deviation of the CFU determination at 1 log
CFU; we calculated that a sample size of 15 would allow us to reliably detect an
effect size of 1 log CFU difference between treated and untreated. After 1 h, mice
were randomized and divided into ﬁve groups (15 mice per groups): groups A and
B received 10 mg/kg P2 IP or UT, respectively, group C received P2Pro2 peptides
(proline substitutions) via UT injection; group D received ampicillin orally as the
positive control, and group E received the vehicle (physiological water). The
catheter was then removed directly after inoculation. After surgery, the animals
were visually monitored for full recovery. Twenty-four hours post infection, mice
were sacriﬁced and organs (kidney, bladder, ureter, colon) were washed with PBS
and homogenized (Thermo Savant FastPrep FP120 Homogenizer/24 s). The
homogenized tissues were serially diluted and were cultured on blood agar plates.
The plates incubated overnight at 37 °C and the rate of bacteria was measured by
CFU value.
Blinding: Sample preparation and treatment of the animals was performed by
La.d.K., L.al.K., who also performed the CFU determination; however, between
treatment and readout, the animals were randomly shufﬂed by F.C. and the key to
the grouping was not revealed until after all the results were received. No animals
were excluded. For the ANOVA analysis of the infection model (Fig. 2f–i), the
assumption that the groups have similar standard deviations was tested using
Bartlett’s test, which showed no signiﬁcant differences between the standard
deviations, except for the ureter data, which we ignored because it was caused by a
reduction in the standard deviation of the untreated group
Construction of E. coliMG1655 dnaK-mCer3. To construct E. coliMG1655 dnaK-
mCer3, plasmid pGBKD-mCer3 was ﬁrst constructed by integrating a mCer3
amplicon, generated with primer pairs 5′-AGAATTCGGCAGCGGCAGCGG-
CAGCGTGAGCAAGGGCGAGGA-3′ (Fw) and 5′-AGGATCCTTACTTGTA-
CAGCTCGTCCA-3′ (Rev), into pGBKDparSpMT140 using EcoRI and BamHI
restriction sites. In addition to adding the respective restriction sites to the end of
the amplicon, these primer pairs also add a ﬂexible linker (encoding GSGSGS41)
facilitating folding of ﬂuorescent fusion proteins constructed with these sequences.
A mCer3-frt-cat-frt cassette was subsequently PCR ampliﬁed from plasmid
pGBKD-mCer3 using primer pairs
5′-AGATGACGATGTTGTCGACGCTGAATTTGAAGAAGTCAAAGA
CAAAAAAGGCAGCG GCAGCGGCA-3′ (Fw) and 5′-AGGAAATTCCCC
TTCGCCCGTGTC AGTATAATTACCCGTTTATAGGGCGA GTGTAGGCTG
GAGCTGCTTC-3′ (Rev).
The amplicon was subsequently inserted into MG1655, creating a C-terminal
DnaK-mCer3 fusion. The cat cassette was subsequently ﬂipped out by transiently
equipping this strain with plasmid pCP2042, resulting in the desired MG1655
dnaK-mCer3 strain.
Protein puriﬁcation for MS analysis. For protein puriﬁcation from SDS gel, the
puriﬁed IBs were loaded on SDS gel (4–15% Mini-PROTEAN® TGX™ Precast
Protein Gels, 10-well, 50 μl well volume) and stained by Coomassie blue (R250).
The excised bands were cut by a sterile scalpel under a laminar ﬂow. The gel slices
washed in several cycles by incubating them in 50 mM ammonium bicarbonate/
acetonitrile (ACN) (1:1) for 10 min at RT until the blue stain is gone and replacing
the buffer by 100% ACN and incubating for 5 min. After the last cycle, the samples
were dried by Speedvac and digested with 250 ng of modiﬁed trypsin (Promega) in
50 mM ammonium bicarbonate buffer (pH 8.3) overnight at 37 °C. Peptides were
extracted by adding 5% ACN+ 0.1% formic acid, and followed by 10% ACN+
0.1% formic acid (FA) and 95% ACN in 0.5% FA and dried by Speedvac. The
extracted peptides were cleaned up by using pierce C18 spin columns (Thermo
Fisher Scientiﬁc) according to the manufacturer’s instructions. The samples were
diluted in 10 μL with 5% ACN+ 0.1% FA for injection in the Q Exactive Orbitrap
mass spectrometer (Thermo Fisher Scientiﬁc, USA).
For gel-free mass spectrometry experiment, dithiothreitol (DTT) solution was
added to puriﬁed IBs (ﬁnal conc. of DTT 0.020M) and incubated for 15 min at RT.
IAA was added to the solution (ﬁnal working conc. 0.050 M) and incubated for
30 min in the dark. ABC (ﬁnal conc. 0.11 M) was added to samples with trypsin
(0.2 μg trypsin to 20 μg protein). To ensure complete protein proteolysis, we
allowed trypsin digestion to proceed for at least 16 h at 37 °C. Thereafter, peptides
were cleaned up using C18 spin Columns (Thermo Fisher Scientiﬁc). According to
the manufacturer’s instructions, the samples were diluted in 10 μL with 5% ACN+
0.1% FA for injection in the Q Exactive Orbitrap mass spectrometer (Thermo
Scientiﬁc, USA).
Analysis of mass spectrometry data. Samples (5 μL) were digested and injected
for UPLC separation using an Ultimate 3000 UPLC System (Dionex, Thermo
Scientiﬁc), using an Acclaim PepMap100 pre-column (C18 3 μm–100 Å, Thermo
Scientiﬁc) and a C18 PepMap RSLC (2 μm, 50 μm–15 cm, Thermo Scientiﬁc) using
a linear gradient (300 μL/min) of 0–4% buffer B (80% ACN, 0.08% FA) for 3 min,
4–10% B for 12 min, 10–35% for 20 min, 35–65% for 5 min, 65–95% for 1 min,
95% for 10 min, 95–5% for 1 min, and 5% for 10 min. The Q Exactive Orbitrap
mass spectrometer (Thermo Scientiﬁc, USA) was operated in positive ion mode
with a nano spray voltage of 1.5 kV and a source temperature of 250 °C. Proteo
Mass LTQ/FT-Hybrid ESI Pos. Mode Cal Mix (MS CAL5-1EASUPELCO, Sigma-
Aldrich) was used as an external calibrant and the lock mass 445.12003 as an
internal calibrant. The instrument was operated in data-dependent acquisition
mode with a survey MS scan at a resolution of 70,000 (fw hm at m/z 200) for the
mass range of m/z 400–1,600 for precursor ions, followed by MS/MS scans of the
top 10 most intense peaks with +2, +3 +4, and +5 charged ions above a threshold
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ion count of 16,000 at 17,500 resolution using normalized collision energy of 25 eV
with an isolation window of m/z3.0 and dynamic exclusion of 10 s. All data were
acquired with Xcalibur 3.0.63 software (Thermo Fisher Scientiﬁc). For identiﬁca-
tion, all raw data were converted into mgf.ﬁles by Proteome Discover version 1.4
(Thermo Fisher Scientiﬁc) and processed using MASCOT version 2.2.06 (Matrix
Science) against the Uniprot E. coli database. The parameters used to search at
MASCOT were: parent tolerance of 10 ppm, fragment tolerance of 0.02 Da, variable
modiﬁcation oxidation of M, ﬁxed modiﬁcation with carbamidomethyl C, and up
to one missed cleavage for trypsin. Results from Mascot were imported to Scaffold
version 3.6.3. The parameters used in Scaffold for protein identiﬁcation were to
retain proteins with 99% conﬁdence and containing at least two identiﬁed peptides
with conﬁdence level 95%.
Nano-FTIR. For mid-IR near-ﬁeld spectroscopy, a commercial scattering-type
scanning near-ﬁeld optical microscopy system was used (Neaspec GmbH, Ger-
many). The system is based on standard AFM technology where a conventional
metal-coated (Pt/Ir) tip is vertically oscillating. The tip acts simultaneously as an
AFM probe and as a near-ﬁeld probe43. Tip and sample were illuminated via a
parabolic mirror objective with a broadband mid-infrared supercontinuum laser
(Neaspec GmbH, max frequency range ca. 650–2,100 cm−1, the average power of
1 mW), which is generated by difference frequency generation. The tip-scattered
light is analyzed with an asymmetric Fourier transform spectrometer where tip and
sample are located in one of the interferometer arms. The detector signal is
demodulated at a frequency O2 (2x AFM tip oscillation frequency) for effective
background suppression. An interferogram is measured by recording the demo-
dulated detector signal as a function of the position of the reference mirror at a
ﬁxed tip position. Subsequent Fourier transform of the recorded interferogram
yields the complex-valued near-ﬁeld point spectrum. The complex spectrum can be
represented as nano-FTIR reﬂectivity and absorption spectra44,45.
Statistical methods. All experiments were performed in minimum three repli-
cates. For statistical evaluation of the determined averages and standard deviations
of the mean, data were analyzed for signiﬁcant differences using the statistical tests
indicated in the ﬁgure legends or text, and included corrections for multiple testing
when required. Statistical calculations were performed using Prism or R, unless
otherwise indicated. Asterisks indicating the level of the P value centered over the
error bar mean: *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
Data availability. Data supporting the ﬁndings of this manuscript are available
from the corresponding authors upon reasonable request. The mass spectrometry
proteomics data have been deposited to the ProteomeXchange Consortium via the
PRIDE46 partner repository with the accession codes PXD008685 and 10.6019/
PXD008685, as well as PXD008701 and 10.6019/PXD008701.
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